Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage. 2009

Cheng-Yun Jin, and Cheol Park, and Sung-Kwon Moon, and Gi-Young Kim, and Taeg Kyu Kwon, and Su Jae Lee, and Wun-Jae Kim, and Yung Hyun Choi
Department of Biomaterial Control (BK21 program), Dongeui University Graduate School, South Korea.

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor superfamily, and it has been shown that many human cancer cell lines are refractory to TRAIL-induced cell death. However, the molecular mechanisms underlying resistance are unclear. In this study, we show that TRAIL resistance is reversed in human hepatoma cells by genistein, an isoflavone found in soy products. Synergistic induction of apoptosis in cells treated with genistein plus TRAIL was associated with cleavage of Bid, a proapoptotic BH3-only protein. Silencing of Bid expression reduced decreases in mitochondrial membrane potential and reduced apoptosis in cells treated with genistein and TRAIL, confirming that Bid cleavage is required for the response. Pretreatment with caspase-3 and caspase-8 inhibitors reduced cotreatment-induced apoptosis. However, treatment with TRAIL alone induced caspase-8 activity that was not different than TRAIL plus genistein; both effectively induced Bid cleavage. These data suggest that genistein abolishes resistance to the Bid cleavage of TRAIL, and that genistein does not interfere with signals upstream of Bid in hepatoma cells.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor
D015853 Cysteine Proteinase Inhibitors Exogenous and endogenous compounds which inhibit CYSTEINE ENDOPEPTIDASES. Acid Cysteine Proteinase Inhibitor,Cysteine Protease Inhibitor,Cysteine Protease Inhibitors,Cysteine Proteinase Antagonist,Cysteine Proteinase Antagonists,Cysteine Proteinase Inhibitor,Cysteine Proteinase Inhibitors, Endogenous,Cysteine Proteinase Inhibitors, Exogenous,alpha-Cysteine Protease Inhibitor,Acid Cysteine Proteinase Inhibitors,alpha-Cysteine Protease Inhibitors,Antagonist, Cysteine Proteinase,Antagonists, Cysteine Proteinase,Inhibitor, Cysteine Protease,Inhibitor, Cysteine Proteinase,Inhibitor, alpha-Cysteine Protease,Inhibitors, Cysteine Protease,Inhibitors, Cysteine Proteinase,Inhibitors, alpha-Cysteine Protease,Protease Inhibitor, Cysteine,Protease Inhibitor, alpha-Cysteine,Protease Inhibitors, Cysteine,Protease Inhibitors, alpha-Cysteine,Proteinase Antagonist, Cysteine,Proteinase Antagonists, Cysteine,Proteinase Inhibitor, Cysteine,Proteinase Inhibitors, Cysteine,alpha Cysteine Protease Inhibitor,alpha Cysteine Protease Inhibitors
D015854 Up-Regulation A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Up-Regulation,Upregulation,Up-Regulation (Physiology),Up Regulation
D015870 Gene Expression The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION. Expression, Gene,Expressions, Gene,Gene Expressions

Related Publications

Cheng-Yun Jin, and Cheol Park, and Sung-Kwon Moon, and Gi-Young Kim, and Taeg Kyu Kwon, and Su Jae Lee, and Wun-Jae Kim, and Yung Hyun Choi
February 2017, The international journal of biochemistry & cell biology,
Cheng-Yun Jin, and Cheol Park, and Sung-Kwon Moon, and Gi-Young Kim, and Taeg Kyu Kwon, and Su Jae Lee, and Wun-Jae Kim, and Yung Hyun Choi
July 2017, Oncology letters,
Cheng-Yun Jin, and Cheol Park, and Sung-Kwon Moon, and Gi-Young Kim, and Taeg Kyu Kwon, and Su Jae Lee, and Wun-Jae Kim, and Yung Hyun Choi
January 2012, Biomolecules & therapeutics,
Cheng-Yun Jin, and Cheol Park, and Sung-Kwon Moon, and Gi-Young Kim, and Taeg Kyu Kwon, and Su Jae Lee, and Wun-Jae Kim, and Yung Hyun Choi
January 2017, Neoplasma,
Cheng-Yun Jin, and Cheol Park, and Sung-Kwon Moon, and Gi-Young Kim, and Taeg Kyu Kwon, and Su Jae Lee, and Wun-Jae Kim, and Yung Hyun Choi
January 2017, OncoTargets and therapy,
Cheng-Yun Jin, and Cheol Park, and Sung-Kwon Moon, and Gi-Young Kim, and Taeg Kyu Kwon, and Su Jae Lee, and Wun-Jae Kim, and Yung Hyun Choi
September 2004, International journal of oncology,
Cheng-Yun Jin, and Cheol Park, and Sung-Kwon Moon, and Gi-Young Kim, and Taeg Kyu Kwon, and Su Jae Lee, and Wun-Jae Kim, and Yung Hyun Choi
June 2012, Bioorganic & medicinal chemistry letters,
Cheng-Yun Jin, and Cheol Park, and Sung-Kwon Moon, and Gi-Young Kim, and Taeg Kyu Kwon, and Su Jae Lee, and Wun-Jae Kim, and Yung Hyun Choi
August 2001, Surgery,
Cheng-Yun Jin, and Cheol Park, and Sung-Kwon Moon, and Gi-Young Kim, and Taeg Kyu Kwon, and Su Jae Lee, and Wun-Jae Kim, and Yung Hyun Choi
January 2014, Hepato-gastroenterology,
Cheng-Yun Jin, and Cheol Park, and Sung-Kwon Moon, and Gi-Young Kim, and Taeg Kyu Kwon, and Su Jae Lee, and Wun-Jae Kim, and Yung Hyun Choi
August 2006, International journal of molecular medicine,
Copied contents to your clipboard!